Home
Search
Policy

Policy

Insights
Browse all insights
News
Browse all news
BIO Statement on Passage of Legislation Reauthorizing the SBIR/STTR Program
March 17, 2026
Announcing Investor Connect Plus: A LaunchBio x BIO Partnership
March 2, 2026
BIO Comments on Global Benchmark for Efficient Drug Pricing (GLOBE) Model (CMS-5545-P)
February 23, 2026
BIO Comments on Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model (CMS-5546-P)
February 23, 2026
Letters, Comments & Testimony
Browse all Letters, Comments & Testimony
BIO Comments on Global Benchmark for Efficient Drug Pricing (GLOBE) Model (CMS-5545-P)
February 23, 2026
BIO Comments on Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model (CMS-5546-P)
February 23, 2026
Letter From BIO President & CEO John F. Crowley to Senate and House Leadership on GLOBE GUARD
February 9, 2026
Dear Mr. Thune, Mr. Schumer, Mr. Johnson, and Mr. Jeffries:As President and CEO of the Biotechnology Innovation Organization (BIO), as a father and entrepreneur whose family is here today because of biotech innovation, and on behalf of the more than 1,000 innovative companies we represent, I write…
Co-Pay Accumulator Programs
Insurers and PBMs are implementing “co-pay accumulator” programs – an effort to prevent funds provided by manufacturer assistance programs from…
International Reference Pricing
Adopting foreign price controls on innovative medicines would severely chill investment in new cures and therapies for diseases and jeopardize access…